Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis. Issue 1 (1st June 2022)

• Record Type: Journal Article
• Authors: Migliorini, Filippo; Colarossi, Giorgia; Eschweiler, Jörg; Oliva, Francesco; Driessen, Arne; Maffulli, Nicola
• Is Part Of: British medical bulletin. Volume 143:Issue 1(2022)
• Page Start: 46
• Page End: 56
• Publication Date: 2022-06-01
• Subjects: corticosteroid -- osteoporosis -- BMD -- fracture -- alendronate -- drugs; Medicine -- Periodicals; 610.5
• DOI: 10.1093/bmb/ldac017
• Languages: English
• ISSNs: 0007-1420

Abstract

Abstract: Introduction: Corticosteroid-induced osteoporosis (CIO) is the most common type of secondary osteoporosis, leading to fractures, and increased morbidity and mortality. Source of data: Pubmed, EMBASE, Scopus and Google Scholar databases. Areas of agreement: Prolonged glucocorticoids administration leads to secondary osteoporosis. Areas of controversy: The optimal management for CIO is controversial. Growing points: The present study compared bone mineral density, fractures and adverse events in patients undergoing treatment with risedronate, alendronate, zoledronate, denosumab or etidronate for CIO. Areas timely for developing research: For selected patients with CIO, alendronate performed better overall. These results must be interpreted within the limitations of the present study. Level of evidence: I, Bayesian network meta-analysis of randomized clinical trials.